Local Coverage Determination (LCD)

Cardiac Radionuclide Imaging

L33457

Expand All | Collapse All

Contractor Information

LCD Information

Document Information

LCD ID
L33457
LCD Title
Cardiac Radionuclide Imaging
Proposed LCD in Comment Period
N/A
Source Proposed LCD
N/A
Original Effective Date
For services performed on or after 10/01/2015
Revision Effective Date
For services performed on or after 06/02/2022
Revision Ending Date
N/A
Retirement Date
N/A
Notice Period Start Date
N/A
Notice Period End Date
N/A
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2022, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity.

CMS National Coverage Policy

Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Title XVIII of the Social Security Act, §1862(a)(7) excludes routine physical examinations.

CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, §220.6.1 PET for Perfusion of the Heart

CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, §220.12 Single Photon Emission Computed Tomograph (SPECT)

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

The two types of radionuclide studies commonly used for cardiac evaluation are myocardial perfusion imaging (MPI) and cardiac blood pool imaging (multiple gated acquisition scanning (MUGA), ventriculography). MPI is used primarily for the evaluation of coronary artery disease (CAD). Ventriculography is sometimes referred to as MUGA or cardiac blood pool imaging and is primarily used to evaluate valvular disease and cardiomyopathies. Either type of study may be obtained at rest or with stress. Stress may be provided by exercise or with pharmacologic agents.

MPI is a diagnostic procedure that evaluates blood flow to cardiac muscle using radionuclides. A gamma camera is used to record images in planar or tomographic (single photon emission computed tomography (SPECT)) projections. Use of dual radiopharmaceuticals permit concurrent studies at rest and after stress, which are then compared and interpreted by a nuclear physician. Since the radiopharmaceutical accumulates in the myocardium in relation to blood flow, ischemic and infarcted myocardium can be detected.

With the use of technetium based radiopharmaceuticals, the perfusion imaging may be linked to acquisition of “first pass” data to visualize blood flow through the right heart, lungs and left heart giving diagnostically useful information about cardiac chamber shunts, wall motion, cardiac output, ejection fraction (EF), left ventricular volume, shunt fraction and valvular regurgitation.

Positron emission tomography (PET) scans performed for the diagnosis and management of patients with known or suspected coronary artery disease, using the Food and Drug Administration (FDA) approved Rubidium 82 (Rb 82), are covered when the following conditions are met:

  • The PET scan (at rest or rest with stress) is performed in place of SPECT; or
  • is performed following and inconclusive SPECT (results that are equivocal, technically uninterpretable, or discordant with the patient’s other clinical data).

In such cases the PET scan must have been determined to be medically necessary to guide further treatment of the patient.

When a PET scan is performed as an additional diagnostic test in the instance of an equivocal SPECT, the reason for performing the PET scan must be clearly documented in the patient’s record.

The following studies are considered investigational and will not be covered:

  • Ambulatory radionuclide cardiac monitoring
  • Monoclonal anti-myosin imaging
  • Radionuclide imaging of thrombi
  • Radionuclide imaging of cardiac adrenergic nerves

Myocardial Perfusion Imaging
Patients with a high pretest probability of disease are usually not candidates for this study unless determination of the size and reversibility of a defect are required for clinical decision making. Patients whose diagnosis is in question benefit most from this study. Patients with a low pretest probability of disease are usually not studied except when a prior exercise stress test by treadmill electrocardiogram (ECG) or echocardiogram (echo) is a presumed false positive. Stress MPI, preceded by satisfactory stress echo, is not medically necessary.

Indications for Myocardial Perfusion Imaging
1. Acute myocardial infarction (AMI) - MPI is not typically performed during the acute period of myocardial infarction (MI), if the diagnosis is established by other means. In selected patients, imaging is appropriate in the assessment of:

    • Disease severity
    • Risk assessment and/or prognosis
    • Efficacy of acute reperfusion therapy
    • Evidence of myocardial salvage
    • Suspected infarction when the combination of history and other tests is not diagnostic.

2. Unstable angina - MPI may be useful as an adjunct to other tests in the diagnosis or treatment of unstable angina only when the combination of history and other tests is not diagnostic. In selected patients, imaging is appropriate for:

    • Identification of ischemia in the distribution of a known lesion or in remote areas
    • Identification of the severity/extent of disease in patients with medically unstable angina or ongoing ischemia
    • Measurement of left ventricular function (LVF).

3. Chronic ischemic heart disease - The use of MPI is well established in the diagnosis and management of CAD and is covered in these situations:

    • Diagnosis of CAD, especially in patients with atypical chest pain
    • Evaluation of abnormal or suspected false positive stress ECG
    • Evaluation of other symptoms suspicious for the diagnosis of CAD such as syncope and ventricular arrhythmia
    • Assessment of myocardial viability after revascularization or medical management
    • Planning percutaneous transluminal coronary angioplasty (PTCA) to identify lesions causing ischemia, if unknown
    • Evaluation of suspected or known CAD prior to high risk surgical procedure
    • Identification of the presence, location, extent, and severity of myocardial ischemia
    • Assessment of drug therapy
    • Assessment of symptoms suggesting restenosis following PTCA
    • Assessment of symptoms suggesting ischemia following Coronary Artery Bypass Graft (CABG)
    • Follow up of symptomatic ischemic heart disease

4. Congenital heart disease (CHD) - Echo is the method of choice for evaluating patients with known or suspected CHD. Selected patients may benefit from MPI when assessing for:

    • Diagnosis of anomalies of the coronary circulation
    • Kawasaki’s disease

5. Post-transplant cardiac disease

    • Assessment of coronary arteriopathy
    • Evaluation for ventricular dysfunction with post-transplant rejection

Cardiac Blood Pool Imaging (MUGA, Ventriculography)
These services are allowed for the evaluation of ventricular size, wall motion, stroke volume, and EF when this information is medically necessary to direct further evaluation and management of the cardiac condition.

Indications for Cardiac Blood Pool Imaging (MUGA, Ventriculography) :
1. Cardiomyopathy - Cardiac blood pool imaging (MUGA, ventriculography) is covered for:

    • Diagnosis of hypertrophic cardiomyopathy and /or myocardial ischemia
    • Differentiation of ischemic from non-ischemic cardiomyopathy

2. Post-transplant cardiac disease

    • Assessment of coronary arteriopathy
    • Evaluation for ventricular dysfunction with post-transplant rejection

3. Assessment of cardiac function for cardiotoxic chemotherapy

    • A. One baseline study is considered medically necessary prior to the initiation of cardiotoxic chemotherapy when one of the following conditions is met:
          1. No echo is planned or performed
          2. Prior echocardiogram is uninterpretable due to poor visualization window
    • B. Cardiac function monitoring during or at the completion of cardiotoxic chemotherapy. Cardiotoxic chemotherapy includes any of the following medications: 
          · 5-FU (5 fluorouracil)
          · Adriamycin® (doxorubicin)
          · Avastin® (bevacizumab)
          · Cerubidine® (daunorubicin)
          · Clolar® (clofarabine)
          · Cytoxan® (cyclophosphamide)
          · Epirubicin (Pharmorubicin®)
          · Gleevec® (imatinib)
          · Herceptin® (trastuzumab)
          · Ifex® (ifosfamide)
          · Mutamycin® (mitomycin)
          · Nexavar® (sorafenib)
          · Novantrone® (mitoxantrone)
          · Sutent® (sunitinib)
          · Taxol® (paclitaxel)
          · Taxotere® (docetaxel)
          · Tykerb® (lapatinib)
          · Valstar® (valrubicin)
          · Xeloda® (capecitabine)
          · Zavedos® (idarubicin)

Pharmacologic Stress Agents
For those patients who are unable to reach 75-100% of their age predicted maximum heart rate by physiologic exercise, vasodilation can be achieved with the use of either dipyridamole or adenosine. Use of pharmacologic agents in MPI is not a standard of care and is not medically necessary unless exercise is not possible. In some cases dobutamine may be used to effect stress through its inotropic effect.

1. Dipyridamole is typically administered intravenously (IV) at 0.57 mg/kg over a 4-minute period. The maximum dose should not exceed 60 mg. Since the dilation effect persists, after injection of the radiopharmaceutical, its effect is typically reversed with IV aminophylline, which must be available to reverse ischemia when it occurs. Dipyridamole is relatively contraindicated in patients with:

    • Known bronchospastic lung disease (asthma)
    • Systemic hypotension (systolic blood pressure (BP) below 100 mm Hg.)
    • AMI less than 48 hours old
    • Unstable angina

2. Adenosine is administered IV at 0.14 mg/kg/min over 6 minutes (0.84mg/kg). The vasodilation effect is short lived. Adenosine is contraindicated in patients with:

    • Second or third degree atrioventricular (AV) block
    • Sinus node disease, except for those with a functioning pacemaker
    • Known or suspected bronchoconstrictive or bronchospastic lung disease
    • Known hypersenstivity to adenosine

3. Dobutamine is administered IV, starting at 0.5-1.0 mcg/kg/min and titrated to reach the maximum heart rate for 2-5 minutes. The maximum dose is 40 mcg/kg/min. Atropine may be added in appropriate doses IV. Dobutamine is contraindicated in patients with:

    • Idiopathic subaortic stenosis
    • AMI

Physician Supervision Requirements
MPI and blood pool imaging require general supervision by a qualified physician licensed to administer radioactive materials. Cardiology stress procedures performed in conjunction with nuclear MPI studies are covered by Medicare only when performed under the direct supervision of a qualified physician, who provides:

    • Medical expertise required for performance of the test
    • Medical treatment for complications and side effects of the test
    • Medical services required as part of the test such as injections of medications
    • Medical expertise in the interpretation of the cardiovascular stress test component, some of which has to be provided during the test and before the patient is discharged from the testing suite
Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

General Information

Associated Information

Documentation Requirements

The patient's medical record must document the medical necessity of services performed for each date of service submitted on a claim, and documentation must be available to the A/B MAC on request.

The medical record must document when significant resting ECG abnormalities are present, or a medication is being used and cannot be withdrawn, that would interfere with interpretation of a stress ECG, resulting in the selection of myocardial perfusion study.

The rationale for selecting pharmacologic stress rather than exercise stress must be indicated in the medical record.

Claims submitted for stress tests performed as preoperative evaluation of patients without symptoms of CAD who are deemed to be at moderate risk must document one of the following at-risk conditions in the medical record: Diabetes mellitus (DM) with complications, peripheral vascular disease (PVD), aortic aneurysm or cerebrovascular disease.

Utilization Guidelines

Services performed for excessive frequency are not medically necessary. Frequency is considered excessive when services are performed more frequently than generally accepted by peers and the reason for additional services is not justified by documentation.

Sources of Information
N/A
Bibliography
  1. Federal Register 1997;62(211):59058-59260.
  2. Glamann DB, Lange RA, Corbett JR, Hillis LD. Utility of various radionuclide techniques for distinguishing ischemic from nonischemic dilated cardiomyopathy. Arch of Intern Med. 1992;152(4):769-72.
  3. Heo J, Iskandrian AS. Technetium-labeled myocardial perfusion agents. Cardiol Clin. 1994;12(2):187-98.
  4. Ritchie JI, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. A report of the American Heart Association/American College of Cardiology task force on assessment of diagnostic and therapeutic cardiovascular procedures, committee on radionuclide imaging, developed in collaboration with the American Society of Nuclear Cardiology. Circulation. 1995;91(4):1278-303.
  5. Watson NE, Cowan RJ, Ball JD. Conventional radionuclide cardiac imaging. Radiol Clin North Am. 1994;32(3):477-500.
  6. Zaret BL, Wackers FJ. Nuclear cardiology (first of two parts). N Engl J Med. 1993;329(11):775-83.
  7. Zaret BL, Wackers FJ. Nuclear cardiology (second of two parts). N Engl J Med. 1993;329(12):855-63.

Revision History Information

Revision History DateRevision History NumberRevision History ExplanationReasons for Change
06/02/2022 R20

Under Coverage Indications, Limitations and/or Medical Necessity added a hyperlink for FDA indications and prescribing information for Rubidium 82 (Rb 82).

  • Provider Education/Guidance
04/22/2021 R19

Under CMS National Coverage Policy corrected headings for the CMS Internet-Only Manual regulations. Under Bibliography changes were made to citations to reflect AMA citation guidelines. Formatting, punctuation and typographical errors were corrected throughout the LCD where applicable.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
10/10/2019 R18

This LCD is being revised in order to adhere to CMS requirements per chapter 13, section 13.5.1 of the Program Integrity Manual, to remove all coding from LCDs. There has been no change in coverage with this LCD revision. Title XVIII of the Social Security Act, §1833(e) was removed from the CMS National Coverage Policy section of this LCD and placed in the related Billing and Coding: Cardiac Radionuclide Imaging A56476 article.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
05/09/2019 R17

Under Coverage Indications, Limitations and/or Medical Necessity – Myocardial Perfusion Imaging, Cardiac Blood Pool Imaging (MUGA, Ventriculography), Pharmacologic Stress Agents and Physician Supervision Requirements removed all HCPCS and CPT® codes listed in each subsection.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
04/11/2019 R16

All coding located in the Coding Information section has been moved into the related Billing and Coding: Cardiac Radionuclide Imaging A56476 article and removed from the LCD.

Under Coverage Indications, Limitations and/or Medical Necessity removed quoted Internet Only Manual (IOM) text and changed verbiage to read “Positron emission tomography (PET) scans performed for the diagnosis and management of patients with known or suspected coronary artery disease, using Food and Drug Administration (FDA) approved Rubidium 82 (Rb 82), are covered when the following conditions are met: The PET scan (at rest or rest with stress) is performed in place of SPECT; or is performed following and inconclusive SPECT (results that are equivocal, technically uninterpretable, or discordant with the patient’s other clinical data). In such cases the PET scan must have been determined to be medically necessary to guide further treatment of the patient. When a PET scan is performed as an additional diagnostic test in the instance of an equivocal SPECT, the reason for performing the PET scan must be clearly documented in the patient’s record.” which starts in the fourth paragraph. Under the subheading Indication for Myocardial Perfusion Imaging removed italics from all five headings. Under Bibliography changes were made to citations to reflect AMA citation guidelines. Formatting, punctuation and typographical errors were corrected, acronyms were inserted, and CPT® was inserted throughout the LCD where applicable.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
11/08/2018 R15

Under Bibliography changes were made to citations to reflect AMA citation guidelines. Formatting, punctuation and typographical errors were corrected throughout the policy.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
10/01/2018 R14

Under ICD-10 Codes that Support Medical Necessity: Group 1 added ICD-10 codes I63.81, I63.89, I67.850 and I67.858. Under ICD-10 Codes that Support Medical Necessity: Group 1 deleted ICD-10 code I63.8. This revision is due to the 2018 Annual ICD-10 Code Update and is effective on October 1, 2018.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To ICD-10-CM Code Changes
02/26/2018 R13 The Jurisdiction "J" Part B Contracts for Alabama (10112), Georgia (10212) and Tennessee (10312) are now being serviced by Palmetto GBA. The notice period for this LCD begins on 12/14/17 and ends on 02/25/18. Effective 02/26/18, these three contract numbers are being added to this LCD. No coverage, coding or other substantive changes (beyond the addition of the 3 Part B contract numbers) have been completed in this revision.
  • Change in Affiliated Contract Numbers
01/29/2018 R12 The Jurisdiction "J" Part A Contracts for Alabama (10111), Georgia (10211) and Tennessee (10311) are now being serviced by Palmetto GBA. The notice period for this LCD begins on 12/14/17 and ends on 01/28/18. Effective 01/29/18, these three contract numbers are being added to this LCD. No coverage, coding or other substantive changes (beyond the addition of the 3 Part A contract numbers) have been completed in this revision.
  • Change in Affiliated Contract Numbers
12/02/2017 R11

 

 

 

 

Revisions were made to the Cardiac Radionuclide Imaging Local Coverage Determination (LCD) L33457. Under Coverage Indications, Limitations and/or Medical Necessity “multiple gated acquisition” and “Percutaneous Transluminal Coronary Angioplasty” verbiage was deleted, the first set of bulleted verbiage was italicized, corrected sentence grammar, corrected the maximum dose of Dobutamine to read “40mcg/kg/min, and the bullets throughout the policy were rearranged. Under CPT/HCPCS Codes, added the Group 3 paragraph verbiage: “Pharmacologic Stress Agents” and the following HCPCS codes were added: J0153, J0280, J0461, J1245, and J1250. Under ICD-10 Codes that Support Medical Necessity, Group 1 Paragraph, Myocardial Perfusion Imaging, added Group 3 codes J0153, J0280, J0461, J1245, and J1250. Under Associated Information corrected the spelling error in the title Documentation Requirements and added “the” to the first paragraph. Under Bibliography corrected the author initials to now read “JI” for the Circulation journal citation.

 

 

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

 

 

 

 

 

 


 

 

 

 

 

 

  • Provider Education/Guidance
  • Other (Annual Validation)
10/01/2017 R10

Under ICD-10 Codes That Support Medical Necessity  Myocardial Perfusion Imaging Group 1: Codes added ICD-10 codes I21.9, I21.A1, I21.A9,  I27.20, I27.21, I27.22, I27.23, I27.24, I27.29, I27.83, I50.810, I50.811, I50.812, I50.813, I50.814, I50.82, I50.83, I50.84, and I50.89. The code description was changed for I50.1. Under ICD-10 Codes That Support Medical Necessity Cardiac Blood Pool Imaging Group 2: Codes added ICD-10 codes I21.9, I21.A1, I21.A9, I27.20, I27.21, I27.22, I27.23, I27.24, I27.29, I27.83, I50.810, I50.811, I50.812, I50.813, I50.814, I50.82, I50.83, I50.84, and I50.89. ICD-10 code I27.2 was deleted. The code description was changed for I50.1. This revision is due to the 2017 Annual ICD-10 Code Updates.

 At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Provider Education/Guidance
  • Revisions Due To ICD-10-CM Code Changes
12/30/2016 R9 Under Coverage Indications, Limitations and/or Medical Necessity the following acronyms were defined: Electrocardiogram (ECG); Percutaneous Transluminal Coronary Angioplasty (PTCA); and Coronary Artery Bypass Graft (CABG).
  • Provider Education/Guidance
10/01/2016 R8 Under ICD-10 Codes That Support Medical Necessity: Group 2 added C58, C81.10, C81.11, C81.12, C81.13, C81.14, C81.15, C81.16, C81.17, C81.18, C81.19, C81.20, C81.21, C81.22, C81.23, C81.24, C81.25, C81.26, C81.27, C81.28, C81.29, C81.30, C81.31, C81.32, C81.33, C81.34, C81.35, C81.36, C81.37, C81.38, C81.39, C81.40, C81.41, C81.42, C81.43, C81.44, C81.45, C81.46, C81.47, C81.48, C81.49, C81.70, C81.71, C81.72, C81.73, C81.74, C81.75, C81.76, C81.77, C81.78 and C81.79. This revision is due to the Annual ICD-10 Code Update and becomes effective October 1, 2016.
  • Provider Education/Guidance
  • Revisions Due To ICD-10-CM Code Changes
05/19/2016 R7 Under ICD-10 Codes That Support Medical Necessity Group 2 added an asterisk to ICD-10 code Z08.
  • Other
01/04/2016 R6 For clarification purposes, multiple gated acquisition scanning (MUGA) and ventriculography were added throughout the LCD to be synonymous with cardiac blood pool imaging. Under CMS National Coverage Policy deleted Title XVIII of the Social Security Act, §1862 (a)(1)(D) Investigational or Experimental and added CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, §§220.6.1 and 220.12. Under Coverage Indications, Limitations and/or Medical Necessity added Indications for Myocardial Perfusion Imaging and Indications for Cardiac Blood Pool Imaging- (MUGA, Ventriculography) and renumbered the indications. A new indication #3 was added under Indications for Cardiac Blood Pool Imaging- (MUGA, Ventriculography) . Under Coverage Indications, Limitations and/or Medical Necessity- Pharmacologic Stress Agents deleted J0151 and added J0153 to the listed HCPCS codes and added CPT codes 78491 and 78492 to the first paragraph. Under #1 corrected the dosage listed to now read 0.57mg/kg. Under #2 corrected the dosage listed to now read 0.14mg/kg/min. Under #3 corrected the dosage listed to now read 0.5-1.0 mcg/kg/min and corrected the maximum dose to read 40mcg/kg. Under ICD-10 Codes That Support Medical Necessity for Myocardial Perfusion Imaging added an asterisk beside Z01.810 and a *Note. Under ICD-10 Codes That Support Medical Necessity for Cardiac Blood Pool Imaging (MUGA, Ventriculography) added ICD-10 codes T45.1X5A, T45.1X5D, T45.1X5S and Z01.89 with asterisks and added a *Note. Under Sources of Information and Basis for Decision corrected the page numbers cited for the Federal Register 1997;62(211):59058-59260. Author initials were corrected for JL Ritchie and the title of the following journal was corrected to now read: Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for Clinical Use of Cardiac Radionuclide Imaging. Report of the American Heart Association/ American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), Developed in Collaboration with the American Society of Nuclear Cardiology. Circulation. 1995;91(4):1278-303. Under Related Local Coverage Documents added the Billing Requirements for Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning –MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy.
  • Provider Education/Guidance
  • Creation of Uniform LCDs Within a MAC Jurisdiction
  • Typographical Error
  • Reconsideration Request
11/16/2015 R5 Under ICD-10 Codes That Support Medical Necessity-Group 2-Blood Pool Imaging CPT codes 78472, 78473, 78481, 78483, 78494, and 78496 added Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm).
  • Provider Education/Guidance
  • Reconsideration Request
10/01/2015 R4 Under ICD-10 Codes that Support Medical Necessity added ICD-10 codes T82.398D and T82.398S.
  • Revisions Due To ICD-10-CM Code Changes
10/01/2015 R3 Per CMS Internet-Only Manual, Pub 100-08, Medicare Program Integrity Manual, Chapter 13, §13.1.3 LCDs consist of only “reasonable and necessary” information. All bill type and revenue codes have been removed.
  • Other (Bill type and/or revenue code removal)
10/01/2015 R2 Under CMS National Coverage Policy removed citation CMS Internet-Only Manuals, Pub 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 4, §220.8 per CR 9095, dated March 27, 2015, effective for dates of service on or after December 18, 2014.
  • Provider Education/Guidance
  • Other (CR 9095 removed 220.8 from the National Coverage Determination Manual.)
10/01/2015 R1 This LCD was made identical to the new A/B MAC ICD-9 LCD that was published for notice.
  • Provider Education/Guidance
  • Creation of Uniform LCDs Within a MAC Jurisdiction
  • Other (Maintenance
    Annual Review)

Associated Documents

Attachments
N/A
Related National Coverage Documents
N/A
Public Versions
Updated On Effective Dates Status
05/27/2022 06/02/2022 - N/A Currently in Effect You are here
04/12/2021 04/22/2021 - 06/01/2022 Superseded View
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

  • Radionuclide Imaging
  • Myocardial Perfusion Imaging
  • Cardiac Blood Pool Imaging
  • Multiple gated acquisition scanning (MUGA)
  • Ventriculography

Read the LCD Disclaimer